MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Sigumir Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Sigumir is the cartilage-and-bone member of the Khavinson "Cytomax" peptide bioregulators, a 10 mg oral capsule of short peptides extracted from young-animal cartilage and bone at the St. Petersburg Institute of Bioregulation and Gerontology. Khavinson's model holds that di- to tetra-peptides penetrate the cell nucleus and bind sequence-specific promoter regions, nudging chondrocyte and osteoblast gene expression (collagen II, SOX9, aggrecan) back toward a younger pattern (PMID 22117547; PMID 37176122). It is marketed for joint, spine and bone support and is usually taken as 1-2 capsules daily with meals for a 30-day course, two to three times a year. Rigorous independent trials of Sigumir itself are lacking; the strongest human data come from a 266-person, 6-8 year St. Petersburg program using related thymus/pineal bioregulators (PMID 14523363). Sigumir is not an approved drug. The subcutaneous figures on this page are an educational unit-conversion reference; the real route is oral.
Reconstitute: Add 1 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 10-20 mg/day orally (1-2 capsules), 30-day course
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Capsules: store in a cool, dry place at room temperature, protected from light and moisture. For the educational lyophilized-vial model: keep powder frozen at −20 °C; after reconstitution refrigerate at 2-8 °C and use within roughly 4 weeks.
Half-life: Not formally established; the constituent ultrashort peptides clear plasma within minutes, while gene-expression effects accrue over 10-15 days and a 30-day course.
Route: Oral 10 mg capsules taken with meals; the subcutaneous reconstitution figures here are an educational measurement reference only, not the real route.
Status: Not FDA- or EMA-approved; sold as a dietary supplement/parapharmaceutical in Russia and some markets, research/educational only elsewhere.
About Sigumir
Sigumir is the cartilage-and-bone bioregulator in Professor Vladimir Khavinson's Cytomax series, a peptide complex (designated A-4; some suppliers list it as Cartilage Cytomax A-8) extracted from the cartilage and bone tissue of young animals at the St. Petersburg Institute of Bioregulation and Gerontology [1][3]. Clinically and commercially it is an ORAL product: 10 mg capsules taken with meals, so every Sigumir dosage figure on this page that references a syringe is an educational reconstitution reference only, not the real-world route.\n\nThe established Sigumir protocol on the label is 1-2 capsules (10-20 mg) per day for a 30-day course, typically repeated two to three times per year [5]. To translate that into the site's standard subcutaneous measurement model we use a 20 mg educational vial reconstituted with 1.0 mL of bacteriostatic water (20 mg/mL), so one capsule-equivalent (10 mg) maps to 50 units on a U-100 insulin syringe and two capsules (20 mg) to 100 units — a full syringe.\n\nFrequency: Once daily with food (the label permits splitting into one or two doses). Sigumir is not approved by the FDA or EMA; the reconstitution, half-life and dosing details below are educational only and are not medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 20 mg educational vial; do not spray it directly onto the peptide, and do not shake.
Swirl gently until the solution is completely clear, giving a 20 mg/mL concentration (200 mcg per insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed units: 10 mg ≈ 50 units, 20 mg ≈ 100 units (a full U-100 syringe).
Educational note: Sigumir is clinically taken ORALLY as 10 mg capsules with meals — this subcutaneous reconstitution is a measurement reference only, and the animal-tissue capsule material is not formulated, purified, or tested for injection.
Interactive Sigumir Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 1mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Initiation — 1 capsule equivalent (10 mg/day) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Standard 30-day course — 2 capsules equivalent (20 mg/day) | 20000 mcg (20 mg) | 100 units (1.00 mL) |
| Maintenance between courses (10 mg/day) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Sigumir, 20 mg each):
- checkA single label 30-day course at 10 mg/day (1 capsule equivalent) uses about 15 vials, since one 20 mg vial covers two days.
- checkFollowing the site's continuous-use convention at 10 mg/day: roughly 28 vials for 8 weeks, 42 for 12 weeks, and 56 for 16 weeks.
- checkAt the 20 mg/day (2-capsule) dose, double these counts — about one 20 mg vial per day.
- checkOrder roughly 10% extra to cover reconstitution loss and syringe dead space.
Insulin Syringes (U-100):
- checkOne syringe per daily injection: about 56 syringes for an 8-week course.
- checkAbout 84 syringes for a 12-week course.
- checkAbout 112 syringes for a 16-week course.
- checkA 0.5 mL, 29-31 G syringe holds the full 100-unit (20 mg) dose in a single draw.
Bacteriostatic Water (30 mL bottles): Use 1.0 mL per vial for reconstitution.
- check8-week model (~28 vials, ~28 mL): one 30 mL bottle.
- check12-week model (~42 vials, ~42 mL): two 30 mL bottles.
- check16-week model (~56 vials, ~56 mL): two 30 mL bottles.
- checkAt the 20 mg/day dose, double the bottle counts.
Alcohol Swabs:
- checkUse 1-2 swabs per session (vial stopper plus injection site).
- checkAbout 120 swabs (roughly one 100-count box) for an 8-week course.
- checkAbout 180 swabs (two boxes) for a 12-week course.
- checkAbout 240 swabs (three boxes) for a 16-week course.
Mechanism of Action (MOA)
Sigumir belongs to the "Cytomax" branch of Vladimir Khavinson's peptide bioregulators — natural complexes obtained by acetic-acid extraction of cartilage and bone tissue from young animals (typically calves), then standardised to roughly 10 mg of peptide per capsule. The active fraction is a mixture of ultrashort peptides (di-, tri- and tetra-peptides) rather than a single defined molecule, which is why no single sequence, molecular weight or receptor is specified for the product [1][3].\n\nThe central hypothesis, developed over four decades at the St. Petersburg Institute of Bioregulation and Gerontology, is epigenetic. Khavinson and colleagues report that short peptides are small enough to cross the cell and nuclear membranes and to bind directly into the major groove of DNA at tissue-specific promoter and regulatory regions. Fluorescence studies showed FITC-labelled Khavinson peptides accumulating in the cytoplasm, nucleus and nucleolus of cultured cells and discriminating between specific deoxyoligonucleotide sequences and methylation states [6]. Molecular-docking work has mapped candidate binding sites for several of these peptides, supporting a "peptide-DNA complementarity" model in which a given peptide preferentially engages a particular promoter and modulates transcription of the genes downstream [2][7].\n\nFor a cartilage-and-bone preparation, the proposed target cells are chondrocytes, osteoblasts and the mesenchymal stem cells that give rise to them. Reviews of chondrogenic peptide regulation describe short peptides influencing the WNT, ERK-p38 and Smad-1/5/8 pathways and the expression of cartilage matrix genes such as collagen type II (COL2), SOX9 and aggrecan (ACAN), the proteins that maintain articular cartilage [3][4]. In the aging-tissue framework, restoring these expression patterns is the claimed basis for Sigumir's marketed use in osteoarthritis, osteoporosis and degenerative spine conditions [1].\n\nPharmacokinetics are not formally characterised for the cytomax. As small peptides they are subject to rapid hydrolysis by gastrointestinal and plasma peptidases, so measurable plasma half-lives for comparable ultrashort peptides are on the order of minutes, and the oral bioavailability of intact peptide is low and undefined. The relevant timescale is pharmacodynamic rather than pharmacokinetic: institute reports describe gene-expression changes appearing within 10-15 days, with the standard course running 30 days — consistent with a slow regulatory signal rather than an acute drug effect [1][5].\n\nTwo honesty caveats matter. First, the real route is oral; the subcutaneous reconstitution scheme on this page is only a unit-conversion convention used across this site, and the animal-derived capsule material is not purified or tested for injection. Second, most of this mechanism rests on work from a single research group, much of it published in Russian-language journals; large, independent, peer-reviewed trials of Sigumir specifically are lacking, so the mechanism should be read as a well-developed hypothesis rather than settled fact [1][5].
Clinical Trial Efficacy Highlights
- starAnisimov and Khavinson (Biogerontology, 2010) summarise four decades of work in which long-term administration of Khavinson peptide bioregulators increased mean lifespan by roughly 20-40% in mice, rats and Drosophila and slowed age-related biomarker changes and tumour development, establishing the geroprotective framework Sigumir is marketed under; these are animal data, not cartilage endpoints [1].
- starKhavinson and Morozov (Neuro Endocrinol Lett, 2003) reported a 6-8 year clinical program in 266 elderly subjects given the related thymus (Thymalin) and pineal (Epithalamin) peptide preparations, describing roughly 2.0-4.1-fold lower mortality versus controls; this is the most-cited human outcome study for the bioregulator class, but it tested other preparations, not Sigumir itself [5].
- starLinkova, Khavinson and colleagues (Int J Mol Sci, 2023) reviewed peptide regulation of chondrogenic stem-cell differentiation, detailing how short peptides modulate the WNT, ERK-p38 and Smad-1/5/8 pathways and upregulate COL2, SOX9 and ACAN — the mechanistic rationale for a cartilage bioregulator, based on in-vitro and review data rather than a Sigumir clinical trial [4].
- starKhavinson and colleagues' systematic review of peptide regulation of gene expression (Molecules, 2021) catalogues dozens of short peptides that alter transcription in a tissue-specific way, including peptides that stimulate osteogenic and chondrogenic differentiation, supporting the plausibility of cartilage- and bone-directed bioregulation [3].
- starFedoreyeva and colleagues (Biochemistry Moscow, 2011) demonstrated that fluorescently labelled Khavinson peptides penetrate the nucleus of HeLa cells and bind specific DNA sequences in vitro, providing direct experimental support for the proposed DNA-interaction mechanism shared by Sigumir's peptide class [6].
- starKhavinson, Lin'kova and Tarnovskaya (Bull Exp Biol Med, 2016) used molecular docking to identify nucleotide binding sites for several short peptides, reinforcing the 'peptide-DNA complementarity' model that underlies the bioregulator concept [2].
- starIndependent, large-scale, peer-reviewed randomised trials of Sigumir specifically for osteoarthritis, osteoporosis or cartilage repair have not been published; manufacturer 'clinical study' reports from the St. Petersburg institute are not indexed peer-reviewed RCTs, so efficacy claims for the finished product remain unproven by conventional evidentiary standards [1][5].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningHuman safety data specific to Sigumir are limited; it has not undergone the controlled toxicology and adverse-event reporting required of an approved drug, so its side-effect profile is not well characterised [1].
- warningBecause the peptides are extracted from animal (bovine) cartilage and bone, people with allergies to animal proteins may react; hypersensitivity and the theoretical risks of animal-tissue sourcing (for example prion/BSE concerns and batch-to-batch quality variation) cannot be fully excluded.
- warningMild gastrointestinal complaints (nausea, stomach discomfort) are the most plausible effects from the oral capsules and are usually managed by taking them with food.
- warningManufacturer labelling lists pregnancy, breastfeeding and childhood as contraindications, advises use only from age 14 onward, and recommends that repeat or chronic-condition courses be taken under physician supervision.
- warningThe subcutaneous route modelled on this page is not validated: injecting a capsule-grade, animal-tissue-derived peptide complex risks injection-site reactions, sterile abscess, infection and immune responses, because the material is not purified, endotoxin-tested or formulated for parenteral use.
- warningFormal drug-interaction studies do not exist; interactions with prescription medicines are unknown, so caution is warranted when combining Sigumir with other therapies.
- warningRegulatory status: Sigumir is not approved by the FDA or EMA. It is sold as a dietary supplement/parapharmaceutical in Russia and a few other markets and is treated as research-use-only elsewhere; long-term human safety has not been established [1][5].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Sigumir dosage?expand_more
The label dosage is 1-2 capsules (10-20 mg of peptide) once daily with meals for a 30-day course, repeated two to three times per year. Sigumir is taken orally; the subcutaneous figures on this page are only an educational unit-conversion (a 20 mg vial in 1.0 mL of bacteriostatic water gives 200 mcg per insulin-syringe unit, so 10 mg ≈ 50 units and 20 mg ≈ 100 units).
Is Sigumir FDA approved?expand_more
No. Sigumir is not approved by the FDA or the EMA for any medical use and is not recognised as a drug in the United States or European Union. In Russia and some other markets it is sold as a dietary supplement or parapharmaceutical; elsewhere it is treated as a research/educational compound. Nothing on this page is medical advice.
What is the half-life of Sigumir, and how long does it take to work?expand_more
A formal half-life has not been published. As ultrashort peptides, the active fractions are broken down by gut and plasma peptidases within minutes, so the compound's value is framed as a slow regulatory signal rather than a sustained blood level. Khavinson-group reports describe gene-expression changes over the first 10-15 days, with the standard benefit window tied to the full 30-day course rather than to peak plasma concentration.
How is Sigumir reconstituted and administered?expand_more
In real-world use Sigumir is not reconstituted at all — it is swallowed as a 10 mg capsule with food. The reconstitution steps here exist only to express the oral dose in syringe units: dissolve a 20 mg educational vial in 1.0 mL of bacteriostatic water for a 20 mg/mL solution. The animal-tissue capsule material is not purified, sterile, or tested for injection, so it should not actually be injected.
Can Sigumir be stacked with other Khavinson bioregulators?expand_more
It commonly is. Khavinson's 'first-class' combination pairs Sigumir (joints and bones) with Endoluten, Vladonix, Cerluten, Svetinorm and Ventfort for different organ systems, and Cartalax (Ala-Glu-Asp-Leu) is the synthesised cartilage 'Cytogen' analog often discussed alongside it. There are, however, no rigorous interaction or combined-safety studies, so any stacking is unstudied and educational only.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Sigumir, plus the universal dosing calculator.
Academic References & Study Citations
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson VKh, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016;162(2):288-292. View Scientific Paper →
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Linkova N, Khavinson V, Diatlova A, Myakisheva S, Ryzhak G. Peptide Regulation of Chondrogenic Stem Cell Differentiation. Int J Mol Sci. 2023;24(9):8415. View Scientific Paper →
Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. View Scientific Paper →
Ilina A, Khavinson V, Linkova N, Petukhov M. Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease. Int J Mol Sci. 2022;23(8):4259. View Scientific Paper →